InvestorsHub Logo

JohnCM

06/02/18 12:48 PM

#1694 RE: PotterBanker #1693

I did too until I read the latest PR.

Checked the share structure.

And looked at the chart.

I am buying at $0.25

JohnCM

06/08/18 12:50 PM

#1696 RE: PotterBanker #1693

Medicine Man MDCL

John,

Thank you for your inquiry. Yes we are DTC eligible. Our ticker symbol is MDCL and we are listed on the OTC Markets as a QB company. Here is a link to our all our current Edgar filings. Thank you

https://www.sec.gov/cgi-bin/browse-edgar?company=Medicine+Man+Technologies&owner=exclude&action=getcompany

JohnCM

06/09/18 12:15 AM

#1697 RE: PotterBanker #1693

"I understand. I read somewhere it takes a month or two.

Thanks again!"

JohnCM

From: Stephanie Van Hassel [mailto:stephanie@medmen.com]
Sent: Friday, June 8, 2018 11:07 PM
To: JohnCM
Subject: Re: MedMen Will Commence Trading May 29th Under Ticker Symbol "MMEN"

Hi John,

The new ticker is not DTC eligible at this moment in time.

Kind regards,
Stéphanie
Sent from my iPhone

On Jun 8, 2018, at 20:52, John wrote:
I have your new sponsored OTC ticker. Do you happen to know if it is DTC eligible yet?

Thank you ... Good move! Reacting and staying flexible. Good sign.

MedMen Revises Executive Compensation Plans

June 08, 2018 05:02 PM Eastern Daylight Time

LOS ANGELES--(BUSINESS WIRE)--MedMen Enterprises Inc. (CSE: MMEN) (“MedMen”), the country’s leading cultivator, producer and retailer of state-sanctioned cannabis, announced today that the grant units for its co-founders under its long-term incentive plan (the “LTIP”) will now vest upon achievement of certain share price goals.

Co-founder and CEO Adam Bierman and Co-founder and President Andrew Modlin will receive their LTIP units of MM Enterprises USA LLC according to the following schedule. One third of the total units will vest when the price of MedMen’s Subordinated Voting Shares reaches CA$ 10 in the open market, another third will vest when the share price reaches CA$ 15 and the final third when the share price reaches CA$ 20. The price will be determined as a 5-day VWAP in any exchange where MedMen shares are traded.

This modification to the grants under the LTIP was made to provide greater economic alignment with MedMen’s shareholders.

About MedMen

MedMen Enterprises is the preeminent cannabis company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America’s addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen employs 800 workers across the United States. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit http://www.medmen.com or follow us on Facebook, Twitter or Instagram.

Source: MedMen Enterprises

Contacts
Media Contact:
Daniel Yi
Senior Vice President of Corporate Communications, MedMen Enterprises
daniel@medmen.com
or
Investor Relations Contact:

"Hello MEDMEN,

I was super excited about Medmen trading publicly in CA and eventually with a U.S. foreign issue OTC ticker. I opened a couple discussion boards on Investors HUB and was truly excited about investing in stock in this company.

I live in the U.S.

And then came the press about the use of the public company initial proceeds and the percentage of the company that individual investors would hold when investing in company shares.

The numbers here are rough and approximate.

Of the $100,000,000 in proceeds, approx half of that went directly into the pockets of the principals.

Roughly 7 percent of the company is owned by investors of company stock.

These numbers are ghastly and I declined to invest in Medmen.

How is the company going to repair its tarnished image with the investment community?"

JohnCM




From: Stéphanie Van Hassel [mailto:stephanie@medmen.com]
Sent: Tuesday, June 5, 2018 1:19 PM
To: John
Subject: Re: MedMen Will Commence Trading May 29th Under Ticker Symbol "MMEN"

MTTPF is not a MedMen sponsored ticker. We will issue a press release with further details if/when MedMen enters the OTC market. If you have not done so already, please sign up for investor alerts on our website.

Kind regards,
Stéphanie

On Tue, Jun 5, 2018 at 11:12 AM, John wrote:
MTTPF

no announcement or mention on website?

Volume, but on the grey sheet.

Perhaps you are waiting for uplist to at least pink?

John

From: Stéphanie Van Hassel [mailto:stephanie@medmen.com]
Sent: Sunday, May 27, 2018 3:55 PM
To: undisclosed-recipients:
Subject: MedMen Will Commence Trading May 29th Under Ticker Symbol “MMEN”

We are thrilled to announce that we are on track to commence trading this coming Tuesday, May 29th on the Canadian Securities Exchange (CSE) under the ticker symbol, MMEN. Additionally, we closed our concurrent financing round on Friday, May 25th, raising CAD 143.0 million at CAD 5.25 per share with a valuation of CAD 2.14 billion.

We thank you for your continued support and interest in MedMen.

Kind regards,
Stéphanie

--
Stéphanie Van Hassel
Head of Investor Relations
C: (917) 650-8671
www.MedMen.com

JohnCM

07/25/18 7:06 PM

#1747 RE: PotterBanker #1693

Medicine Man Technologies Provides a Positive Outlook for 2018 Financial Performance and a General Corporate Update

Denver, CO, July 25, 2018 (GLOBE NEWSWIRE)

Medicine Man Technologies Inc. (MDCL) (“Medicine Man Technologies” or “Company”), one of the United States' leading cannabis branding and consulting companies today provided the following update.

The Company projects the following revenue and profitability performance metrics:

Projects a 14% 2nd quarter revenue growth to $1,380,000 over the $1,120,000 as reported in the 1st quarter of FY 2018

Projects a 57% 2nd quarter FY 2018 revenue growth to $1,380,000 over the $882,000 as reported in the 2nd quarter in FY 2017

Projects it will report a 6th consecutive quarter of revenue growth in addition to a 2nd consecutive quarter of profitability related to FY 2018

Projects a 225% 3rd quarter 2018 revenue growth to $4,500,000 over the $1,380,000 as projected for its 2nd quarter in FY 2018

Projects a 385% 3rd quarter 2018 revenue growth to $4,500,000 over the $965,000 as reported in the 3rd quarter period in 2017.

Projects it will report a 7th consecutive quarter of revenue growth in addition to profitability for its 3rd quarter of operations.

Projects a 156% growth in revenues to $9,000,000 for FY 2018 in comparison to the $3,529,000 as reported in FY 2017.

Projects profitability for FY 2018 noting the combination of Q1 and projected Q2 profits are projected to reach $100,000 based upon the projection of approximately $2,500,000 of revenues

Since its last client update in mid-April of 2018, the Company has entered several new license and/or service agreements with clients in Arkansas, Oklahoma, and Michigan in addition to the one new Canadian based master licensing agreement as announced earlier this month with the Canada House Wellness Group (CSE:CHV).

The Company expects with its Q2 filing in August to qualify as well as file its application for a QX status listing, having engaged a highly qualified sponsor and as expected to be able to meet the criteria as currently listed for such status on the OTC Marketplace. We expect by the end of the 3rd quarter to have achieved QX status.

The Company expects to file its second quarter 10Q report prior to the published August 14th deadline and will also host an investor call to discuss its performance on a date and time to be announced shortly.

Brett Roper, Medicine Man Technologies’ co-founder and CEO commented, “We are pleased with the continuation of our ability to post solid operational results as projected for the second quarter of 2018, highlighted by the projected achievement of both a sixth consecutive revenue growth quarter and second consecutive profitable quarter in FY 2018. We believe that this performance has the Company firmly on track to achieving its general profitability goals for the year.”

Andy Williams, Chairperson of Medicine Man Technologies’ Board of Directors added, “We are keenly focused on our evolution into a Cannabis or “plant touching” related operating company and feel that next year will provide for an extraordinary opportunity for license holders here in Colorado to flourish.

We will initially be exploring equity and operating opportunities outside of Colorado and have already begun to provide initial corporate development strategy services to several businesses here in Colorado in anticipation of a re-vitalized HB 18-1011 initiative moving into 2019. We truly believe the balance of 2018 and moving into 2019 will provide us with a significant number of new opportunities to expand our business both here in the US as well as internationally."

About Medicine Man Technologies, Inc.

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, the Company has provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. The Company currently has or has had active clients in California, Iowa, Oregon, Colorado, Nevada, Illinois, Michigan, Arkansas, Pennsylvania, Florida, Ohio, Maryland, New York, Massachusetts, Puerto Rico, Canada, Australia, Germany, and South Africa. We continue to focus on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company's highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will "share" the ever-improving experience and knowledge of the network, and 5) continuing the expansion of our Brands Warehouse concept through entry into industry based cooperative agreements and pursuing other acquisitions as they prove suitable to our overall business development strategy.

JohnCM

07/29/18 5:41 AM

#1752 RE: PotterBanker #1693

JohnCM

07/29/18 5:46 AM

#1753 RE: PotterBanker #1693

CV Sciences

CVSI


CONTACT DETAILS

2688 South Rainbow Boulevard

Suite B

Las Vegas, NV 89146

www.cvsciences.com

(866) 290-2157

info@cvsciences.com

DESCRIPTION

CV Sciences, Inc. is a life science company that operates through two segments, specialty pharmaceuticals and consumer products. The Company focuses on developing and commercializing proprietary prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient and is engaged in the development, manufacturing, marketing and sale of consumer products containing plant-based CBD, which is refined into its own proprietary branded products. CV Sciences initial drug candidate (CVSI-007) is a chewing gum that combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at $2 billion, growing to over $4 billion in the next 5-6 years.

SECURITY DETAILS

Market Cap
248,253,919
07/27/2018

Shares Out
91,945,896
06/29/2018